MarketPulse

Tzield

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Tzield Wins FDA Nod to Treat Type 1 Diabetes in Infants as Young as One

FDA approves Sanofi's Tzield for children as young as one with type 1 diabetes, marking first disease-modifying therapy for this young cohort.
SNYFDA approvalType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Tzield Wins FDA Approval to Treat Type 1 Diabetes in Younger Children

FDA approves $SANF's Tzield for children ages 1+ with stage 2 type 1 diabetes, expanding from prior 8+ restriction. First disease-modifying therapy for autoimmune condition.
SNYFDA approvalTzield